GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibrx Biosciences Inc (NAS:INBX) » Definitions » ROCE %

INBX (Inhibrx Biosciences) ROCE % : 7,127.18% (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Inhibrx Biosciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Inhibrx Biosciences's annualized ROCE % for the quarter that ended in Jun. 2024 was 7,127.18%.

Inhibrx Biosciences ROCE % Historical Data

The historical data trend for Inhibrx Biosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibrx Biosciences ROCE % Chart

Inhibrx Biosciences Annual Data
Trend Dec22 Dec23
ROCE %
- -

Inhibrx Biosciences Quarterly Data
Dec22 Mar23 Jun23 Dec23 Mar24 Jun24
ROCE % Get a 7-Day Free Trial - - - - 7,127.18

Inhibrx Biosciences ROCE % Calculation

Inhibrx Biosciences's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-152.747/( ( (16.645 - 20.772) + (26 - 32.863) )/ 2 )
=-152.747/( (-4.127+-6.863)/ 2 )
=-152.747/-5.495
=2,779.75 %

Inhibrx Biosciences's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2024 )  (Q: Mar. 2024 )(Q: Jun. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2024 )  (Q: Mar. 2024 )(Q: Jun. 2024 )
=7453.496/( ( (28.222 - 38.431) + (258.418 - 39.052) )/ 2 )
=7453.496/( ( -10.209 + 219.366 )/ 2 )
=7453.496/104.5785
=7,127.18 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inhibrx Biosciences  (NAS:INBX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Inhibrx Biosciences ROCE % Related Terms

Thank you for viewing the detailed overview of Inhibrx Biosciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibrx Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibrx Biosciences Inc (NAS:INBX) » Definitions » ROCE %
Comparable Companies
Traded in Other Exchanges
N/A
Address
11025 N. Torrey Pines Road, Suite 140, La Jolla, CA, USA, 92037
Website
https://www.inhibrx.com
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.